Is HCV genotyping cost-effective even when the prevalences of genotypes 2 and 3 are low?

摘要: BACKGROUND/AIMS The management of chronic hepatitis C virus (HCV) infection is costly. Genotyping determines the indication, probability response, and duration treatment dose ribavirin. Although genotyping accepted cost-effective, cost in all patients to find out a minority may offset gain. present study aimed; (1) determine frequency rate HCV genotypes (2) compare tailored according genotype versus that planned supposing it be 1. METHODOLOGY Six centers were included into study. Name, age, genotype, serotype each patient entered. For genotyping, HCV-RNA was extracted by acid-guanidium-phenol-chloroform method. Cost studies with pegylated interferon ribavirin estimated. determined two scenarios: (A) To manage as if had other than 2-3. (B) them after determining geno type. assumed made current guidelines. RESULTS data 834 analyzed: Genotypel predominant: 730 (87.5%). rest composed G2:26 (3.1%), G3:26 G4:14 (1.7%), mixed: 13 (1.6%), undetermined: 25(3%). approach A (for 100 patients) 1,718,200 USD; B 1,671,900 USD. With targeted therapy, every would save 46,300 CONCLUSIONS prevalent our country genotypel. sum 2 3 corresponds 6%. tailoring thereafter are cost-effective even countries where prevalence these low.